CD274 and non-small cell lung carcinoma: However, the KEYNOTE–598 trial did not support the improvement in efficacy of adding ipilimumab to pembrolizumab, but increased toxicity, as the 1st–line treatment for patients with NSCLC with PD–L1 TPS of at least 50% (65).